[go: up one dir, main page]

PE20181175A1 - Sales de un inhibidor de lsd1 - Google Patents

Sales de un inhibidor de lsd1

Info

Publication number
PE20181175A1
PE20181175A1 PE2018000222A PE2018000222A PE20181175A1 PE 20181175 A1 PE20181175 A1 PE 20181175A1 PE 2018000222 A PE2018000222 A PE 2018000222A PE 2018000222 A PE2018000222 A PE 2018000222A PE 20181175 A1 PE20181175 A1 PE 20181175A1
Authority
PE
Peru
Prior art keywords
salts
lsd1
methyl
lsd inhibitor
preparation
Prior art date
Application number
PE2018000222A
Other languages
English (en)
Inventor
Qun Li
Yongchun Pan
Wayne Han
Ganfeng Cao
William Frietze
Zhongjiang Jia
Vaqar Sharief
Jiacheng Zhou
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of PE20181175A1 publication Critical patent/PE20181175A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Referido a una sal de tosilato de acido 1-{[4-(metoximetil)-4-({[(1R,2S)-2-fenilciclopropil]amino} metil)piperidin-1-il]metil}ciclobutancarboxilico o un hidrato o solvato de esta; metodos para su preparacion e intermedios en su preparacion, el cual es un inhibidor de demetilasa especifica para lisina (LSD1), siendo utiles en el tratamiento de enfermedades asociadas a LSD1 o mediadas por esta, tales como cancer
PE2018000222A 2015-08-12 2016-08-11 Sales de un inhibidor de lsd1 PE20181175A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562204105P 2015-08-12 2015-08-12
US201662326246P 2016-04-22 2016-04-22

Publications (1)

Publication Number Publication Date
PE20181175A1 true PE20181175A1 (es) 2018-07-20

Family

ID=56740526

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000222A PE20181175A1 (es) 2015-08-12 2016-08-11 Sales de un inhibidor de lsd1

Country Status (35)

Country Link
US (3) US10329255B2 (es)
EP (1) EP3334709B1 (es)
JP (1) JP7427363B2 (es)
KR (1) KR102710120B1 (es)
CN (1) CN110402244B (es)
AU (1) AU2016306555B2 (es)
BR (1) BR112018002553A8 (es)
CA (1) CA2995361A1 (es)
CL (1) CL2018000374A1 (es)
CO (1) CO2018002354A2 (es)
CR (1) CR20180152A (es)
DK (1) DK3334709T3 (es)
EA (1) EA035534B1 (es)
EC (1) ECSP18018869A (es)
ES (1) ES3011209T3 (es)
FI (1) FI3334709T3 (es)
HR (1) HRP20250161T1 (es)
HU (1) HUE070538T2 (es)
IL (1) IL257390B (es)
LT (1) LT3334709T (es)
MA (1) MA42606B1 (es)
MX (1) MX389824B (es)
MY (1) MY189367A (es)
PE (1) PE20181175A1 (es)
PH (1) PH12018500317B1 (es)
PL (1) PL3334709T3 (es)
PT (1) PT3334709T (es)
RS (1) RS66537B1 (es)
SG (1) SG10202001219UA (es)
SI (1) SI3334709T1 (es)
SM (1) SMT202500084T1 (es)
TW (1) TWI765860B (es)
UA (1) UA126277C2 (es)
WO (1) WO2017027678A1 (es)
ZA (1) ZA201801417B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59534B1 (sr) 2014-02-13 2019-12-31 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
ES2672797T3 (es) 2014-02-13 2018-06-18 Incyte Corporation Ciclopropilaminas como inhibidores de LSD1
PH12020552066A1 (en) 2014-02-13 2022-05-11 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
EP3626720A1 (en) 2015-04-03 2020-03-25 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
MX389824B (es) 2015-08-12 2025-03-20 Incyte Holdings Corp Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1).
SG10201913331VA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
JP2019512546A (ja) 2016-03-16 2019-05-16 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｋｄｍ１ａ標的会合を決定するための方法、およびそれに有用な化学プローブ
IL262488B (en) * 2016-04-22 2022-08-01 Incyte Corp lsdi inhibitor formulations
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
MA51507A (fr) 2016-12-09 2020-11-11 Constellation Pharmaceuticals Inc Marqueurs pour un traitement personnalisé du cancer avec des inhibiteurs de lsd1
FI3661510T3 (fi) 2017-08-03 2024-12-18 Oryzon Genomics Sa Menetelmiä käyttäytymismuutosten hoitamiseksi
WO2019083971A1 (en) 2017-10-23 2019-05-02 Children's Medical Center Corporation METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY
CA3106484C (en) * 2018-07-20 2024-06-25 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. A salt of an lsd1 inhibitor and its crystal form
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
EP3851440A4 (en) * 2018-09-13 2022-06-08 Helioeast Pharmaceutical Co., Ltd. Cyclopropylamine compound as lsd1 inhibitor and use thereof
CN113613653A (zh) 2019-03-20 2021-11-05 奥莱松基因组股份有限公司 治疗边缘型人格障碍的方法
WO2020188089A1 (en) 2019-03-20 2020-09-24 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
WO2021004610A1 (en) 2019-07-05 2021-01-14 Oryzon Genomics, S.A. Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
WO2022214303A1 (en) 2021-04-08 2022-10-13 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
GB202115017D0 (en) 2021-10-20 2021-12-01 Univ London Queen Mary Sequential treatments and biomarkers to reverse resistance to kinase inhibitors
WO2023067058A1 (en) 2021-10-20 2023-04-27 Queen Mary University Of London Sequential treatments and biomarkers to reverse resistance to kinase inhibitors
EP4522137A1 (en) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
EP4522136A1 (en) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
KR20250109775A (ko) 2022-11-24 2025-07-17 오리존 지노믹스 에스.에이. 암 치료를 위한 lsd1 억제제 및 메닌 억제제의 조합
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
KR20250024570A (ko) * 2023-08-09 2025-02-19 전남대학교산학협력단 골질환 예방 또는 치료용 약학 조성물
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (318)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7013068A (es) 1969-09-17 1971-03-19
US4537889A (en) 1982-12-27 1985-08-27 Eli Lilly And Company Inotropic agents
US4625040A (en) 1984-09-24 1986-11-25 Pennwalt Corporation N-(phenyl) or N-(phenylcyclopropyl)-2,5-dihydro-2-oxo-4[(substituted phenyl)amino]-3-furancarboxamide derivatives
US4614810A (en) 1984-09-24 1986-09-30 Pennwalt Corporation 4,5-dihydro-4-oxo-2-[(2-trans-phenylcyclopropyl)amino]-3-furancarboxylic acids and derivatives thereof
FR2607813B1 (fr) 1986-12-05 1989-03-31 Montpellier I Universite Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
AU622330B2 (en) 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
JP2844351B2 (ja) 1989-07-13 1999-01-06 株式会社科薬 安定なポリミキシン系抗生物質水性溶液
IL96432A0 (en) 1989-11-30 1991-08-16 Schering Ag Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
FR2662163A1 (fr) 1990-05-16 1991-11-22 Lipha Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant.
DE69323883T2 (de) 1992-06-17 1999-07-22 Pharmacia & Upjohn Co., Kalamazoo, Mich. Pyrridino-, pyrrolidino- und azepino-substituierte oxime als antiatherosklerosemittel und antihypercholesterolemiemittel
JP2923139B2 (ja) 1992-10-05 1999-07-26 三井化学株式会社 製 剤
DE4327027A1 (de) 1993-02-15 1994-08-18 Bayer Ag Imidazoazine
FR2711993B1 (fr) 1993-11-05 1995-12-01 Rhone Poulenc Rorer Sa Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation.
US5932223A (en) 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
TR200001728T2 (tr) 1997-11-11 2000-09-21 Ono Pharmaceutical Co., Ltd. Birleşik pirazin türevleri
JP2000319277A (ja) 1999-05-11 2000-11-21 Ono Pharmaceut Co Ltd 縮合ピラジン化合物およびその化合物を有効成分とする薬剤
JP2000319278A (ja) 1999-05-11 2000-11-21 Ono Pharmaceut Co Ltd 縮合ピラジン化合物およびその化合物を有効成分とする薬剤
JP4032566B2 (ja) 1999-06-21 2008-01-16 東レ株式会社 発光素子
JP4041624B2 (ja) 1999-07-21 2008-01-30 三井化学株式会社 有機電界発光素子
JP2001057292A (ja) 1999-08-20 2001-02-27 Toray Ind Inc 発光素子
CN101804041A (zh) 1999-09-28 2010-08-18 灵药生物技术有限公司 含有尼美舒利的控释组合物
SE9903611D0 (sv) 1999-10-06 1999-10-06 Astra Ab Novel compounds III
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
JP4409680B2 (ja) 1999-10-18 2010-02-03 株式会社ヤクルト本社 三環性縮合イミダゾール誘導体
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
KR100830859B1 (ko) 2000-04-27 2008-05-21 아스텔라스세이야쿠 가부시키가이샤 이미다조피리딘 유도체 및 이를 함유하는 의약 조성물
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
HUP0301801A2 (hu) 2000-07-14 2003-09-29 Bristol-Myers Squibb Pharma Company Imidazo[1,2-a]pirazin-származékok és az ezeket tartalmazó gyógyszerkészítmények
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
WO2002034748A1 (fr) 2000-10-24 2002-05-02 Sankyo Company, Limited Derives d'imidazopyridine
JP2002205992A (ja) 2000-11-08 2002-07-23 Takeda Chem Ind Ltd 二環式トリアゾロン誘導体およびそれを含有する除草剤
JP4302980B2 (ja) 2000-11-10 2009-07-29 メルク シャープ エンド ドーム リミテッド Ｇａｂａ受容体リガンドとしてのイミダゾ−トリアジン誘導体
WO2002048146A2 (de) 2000-12-13 2002-06-20 Basf Aktiengesellschaft Verwendung von substituierten imidazoazinen, neue imidazoazine, verfahren zu deren herstellung, sowie sie enthaltende mittel
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
WO2002072549A1 (en) 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
AU2003214873A1 (en) 2002-01-18 2003-09-02 Ceretek Llc Methods of treating conditions associated with an edg receptor
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
CA2502148A1 (en) 2002-10-16 2005-02-17 Board Of Regents, The University Of Texas System Methods and compositions for increasing the efficacy of biologically-active ingredients
WO2004058176A2 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Acyclic pyrazole compounds
US7189723B2 (en) 2003-02-10 2007-03-13 Cgi Pharmaceuticals, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
NZ542304A (en) 2003-03-14 2009-07-31 Ono Pharmaceutical Co Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
DE602004025220D1 (de) 2003-04-11 2010-03-11 High Point Pharmaceuticals Llc Pharmazeutische verwendungen von kondensierten 1,2,4-triazolen
AU2004233828B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
CN102417508A (zh) 2003-07-14 2012-04-18 艾尼纳制药公司 作为新陈代谢调节剂的稠合芳基和杂芳基衍生物以及预防和治疗与其相关的病症
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
EP1663193B1 (en) 2003-09-12 2012-04-04 Merck Serono SA Sulfonamide derivatives for the treatment of diabetes
JP2005089352A (ja) 2003-09-16 2005-04-07 Kissei Pharmaceut Co Ltd 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
BRPI0415185A (pt) 2003-10-10 2006-11-28 Pfizer Prod Inc 2h-[1,2,4]triazol[4,3-a]pirazinas substituìdas como inibidores da gsk-3
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
WO2005044793A2 (en) 2003-10-31 2005-05-19 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
EP1698335A4 (en) 2003-12-26 2007-08-01 Ono Pharmaceutical Co AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR
EP1717238A4 (en) 2004-02-16 2008-03-05 Daiichi Seiyaku Co FUNGICIDES HETEROCYCLIC COMPOUNDS
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
ES2517244T3 (es) 2004-05-11 2014-11-03 Egalet Ltd. Forma farmacéutica hinchable que comprende goma gellan
WO2006131003A1 (en) 2005-06-09 2006-12-14 Oncalis Ag Angiogenesis inhibitors
TW200612918A (en) 2004-07-29 2006-05-01 Threshold Pharmaceuticals Inc Lonidamine analogs
EP1781655A2 (en) 2004-08-18 2007-05-09 Pharmacia & Upjohn Company LLC Triazolopyridine compounds useful for the treatment of inflammation
MX2007002679A (es) 2004-09-02 2007-05-16 Smithkline Beecham Corp Compuestos quimicos.
WO2006038116A2 (en) 2004-10-07 2006-04-13 Warner-Lambert Company Llc Triazolopyridine derivatives as antibacterial agents
CA2587210A1 (en) 2004-11-22 2006-06-01 Threshold Pharmaceuticals, Inc. Tubulin binding anti cancer agents and prodrugs thereof
DE602005016718D1 (de) 2004-12-01 2009-10-29 Merck Serono Sa Coinsins Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen
WO2007149479A1 (en) 2006-06-22 2007-12-27 Mallinckrodt Inc. Pyrazine derivatives and uses thereof in renal monitoring
WO2006073938A2 (en) 2004-12-30 2006-07-13 East Carolina University Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
NZ556627A (en) * 2005-02-22 2010-09-30 Pfizer Oxyindole derivatives as 5HT4 receptor agonists
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
AR053712A1 (es) 2005-04-18 2007-05-16 Neurogen Corp Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide)
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7709468B2 (en) 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
DE602006016455D1 (de) 2005-09-09 2010-10-07 Schering Corp Neue 4-cyano-, 4-amino-, und 4-aminomethylderivative von pyrazoloä1,5-aüpyridinen, pyrazoloä1,5-cüpyrimidinen und 2h-indazolverbindungen und 5-cyano-, 5-amino- und 5-aminomethylderivative von imidazoä1,2-aüpyridinen, und imidazoä1,5-aüpyrazinverbindungen als inhibitoren der cyclinabhänggen kinase
CN101370811A (zh) 2005-11-10 2009-02-18 先灵公司 作为蛋白激酶抑制剂的咪唑并吡嗪化合物
CN101583620B (zh) 2005-11-28 2016-08-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
BRPI0620760A2 (pt) 2005-12-27 2011-11-22 Hoffmann La Roche derivados de aril-isoxazol-4-il-imidazo[1,5]piridina
WO2007074491A1 (en) 2005-12-28 2007-07-05 Universita Degli Studi Di Siena HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
RU2008143179A (ru) 2006-03-31 2010-05-10 Новартис АГ (CH) Органические соединения
CN101516883A (zh) 2006-06-06 2009-08-26 先灵公司 作为蛋白激酶抑制剂的咪唑并吡嗪化合物
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
US9216963B2 (en) 2006-06-22 2015-12-22 Medibeacon Inc. Pyrazine derivatives with extended conjugation and methods of using the same in optical applications
AU2007269830A1 (en) 2006-06-29 2008-01-10 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
WO2008005423A1 (en) 2006-07-03 2008-01-10 Cambrex Charles City, Inc. Improved method of making sufentanil
WO2008005908A2 (en) 2006-07-07 2008-01-10 Forest Laboratories Holdings Limited Pyridoimidazole derivatives
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US20080021217A1 (en) 2006-07-20 2008-01-24 Allen Borchardt Heterocyclic inhibitors of rho kinase
US7563797B2 (en) 2006-08-28 2009-07-21 Forest Laboratories Holding Limited Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands
DE102006041292A1 (de) 2006-09-01 2008-03-06 Henkel Kgaa Wasserstoffperoxid-Aktivierung mit N-Heterocyclen
WO2008037607A1 (de) 2006-09-25 2008-04-03 Basf Se Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen
ES2377821T3 (es) 2006-10-11 2012-04-02 Amgen Inc. Compuestos de imidazo- y triazolo-piridina y métodos de uso de los mismos.
JP2010509363A (ja) 2006-11-08 2010-03-25 ノババックス，インコーポレイテッド 固体剤形の多相医薬組成物の製造方法
EA018378B1 (ru) 2006-11-08 2013-07-30 Ньюрокрайн Байосайенсиз, Инк. ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
WO2008056176A1 (en) 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
DK2497470T3 (en) 2006-11-22 2015-12-07 Incyte Holdings Corp Imidazotriaziner and imidazopyrimidines as kinase inhibitors
JP2010511018A (ja) 2006-12-01 2010-04-08 ガラパゴス・ナムローゼ・フェンノートシャップ 変性疾患及び炎症性疾患の治療に有用なトリアゾロピリジン化合物
WO2008079404A2 (en) 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
EP2118101B1 (en) 2007-03-09 2012-09-26 Probiodrug AG Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
EP1972628A1 (en) 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizines and aza-analog derivatives thereof as CNS active compounds
EP2146989B1 (en) 2007-04-16 2012-01-04 Leo Pharma A/S Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
EP2142551B1 (en) 2007-04-17 2015-10-14 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
PT2155747E (pt) 2007-05-10 2012-12-19 Ge Healthcare Ltd Imidazol(1,2-a)piridinas e compostos relacionados com actividade nos receptores de canabinóides cb2
US9084817B2 (en) 2007-05-21 2015-07-21 Toray Industries, Inc. Oral preparation comprising specific organic acid, and method for improvement in elution property and chemical stability of oral preparation
CN101790526A (zh) 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
EP2170892A2 (en) 2007-06-14 2010-04-07 Schering Corporation Imidazopyrazines as protein kinase inhibitors
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
CA2693232A1 (en) 2007-07-18 2009-01-22 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
MX2010001340A (es) 2007-07-31 2010-06-02 Schering Corp Combianacion de agente antimitotico e inhibidor de aurora quinasa como tratamiento anticancerigeno.
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
WO2009023179A2 (en) 2007-08-10 2009-02-19 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
US20090047336A1 (en) 2007-08-17 2009-02-19 Hong Kong Baptist University novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation
FR2920090A1 (fr) 2007-08-24 2009-02-27 Oreal Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine particuliere, un coupleur et un tensioactif particulier.
FR2920091A1 (fr) 2007-08-24 2009-02-27 Oreal Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine, un coupleur et un polyol particulier.
KR20090022616A (ko) 2007-08-31 2009-03-04 한올제약주식회사 베실산클로피도그렐 함유 경구투여용 약제
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
ME01999B (me) * 2007-10-11 2015-05-20 Astrazeneca Ab Derivati pirolo[2,3-d]pirimidina kao inhibitori protein kinaze b
WO2009048993A2 (en) 2007-10-12 2009-04-16 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
DK2231662T3 (da) 2007-12-19 2011-08-29 Genentech Inc 8-Anilinoimidazopyridiner og deres anvendelse som anticancer- og/eller antiinflammatoriske midler
WO2009085230A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Inhibitors of pi3 kinase
KR100988233B1 (ko) 2007-12-26 2010-10-18 한미홀딩스 주식회사 클로피도그렐 1,5-나프탈렌 다이술폰산 염 또는 이의수화물의 약학 조성물 및 제제
SI2288610T1 (sl) 2008-03-11 2016-11-30 Incyte Holdings Corporation Derivati azetidina in ciklobutana kot inhibitorji jak
PL2262505T3 (pl) 2008-03-12 2015-04-30 Intra Cellular Therapies Inc Podstawione heterocykliczne skondensowane gamma-karboliny w postaci stałej
CA2718403A1 (en) 2008-03-13 2009-09-17 The General Hospital Corporation Inhibitors of the bmp signaling pathway
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
EP2444403A1 (en) 2008-04-18 2012-04-25 Shionogi Co., Ltd. Heterocyclic compound having inhibitory activity on PI3K
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
US8349210B2 (en) 2008-06-27 2013-01-08 Transitions Optical, Inc. Mesogenic stabilizers
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
TR200806298A2 (tr) 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Farmasötik formülasyon
US20120021519A1 (en) 2008-09-19 2012-01-26 Presidents And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
JP2010070503A (ja) 2008-09-19 2010-04-02 Daiichi Sankyo Co Ltd 抗真菌作用２−アミノトリアゾロピリジン誘導体
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2376490B1 (en) 2008-12-04 2013-01-23 Proximagen Limited Imidazopyridine compounds
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
US20100209489A1 (en) 2009-02-04 2010-08-19 Supernus Pharmaceuticals, Inc. Formulations of desvenlafaxine
EP2393813B1 (en) 2009-02-04 2013-07-31 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 ß-hydroxysteroid dehydrogenase 1 useful for the treatment of diseases related to elevated level of cortisol
TR200900879A2 (tr) 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler
TR200900878A2 (tr) 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar
EP2396331B1 (en) 2009-02-13 2013-10-16 Bayer Intellectual Property GmbH Fused pyrimidines as akt inhibitors
KR20100101054A (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
WO2010107404A1 (en) 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations
AR076052A1 (es) 2009-03-20 2011-05-18 Incyte Corp Derivados de pirimidinas sustituidas, composiciones farmaceuticas que los contienen y uso de los mismos en trastornos asociados con receptores de histamina h4, tales como trastornos inflamatorios, prurito y dolor.
WO2010113942A1 (ja) 2009-03-31 2010-10-07 キッセイ薬品工業株式会社 インドリジン誘導体及びその医薬用途
AU2010238361B2 (en) 2009-04-16 2015-08-06 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Imidazopyrazines for use as kinase inhibitors
TWI461426B (zh) 2009-05-27 2014-11-21 Merck Sharp & Dohme （二氫）咪唑並異〔５，１－ａ〕喹啉類
MX2011013437A (es) 2009-06-10 2012-02-21 Sunovion Pharmaceuticals Inc Antagonista y agonistas inversos de histamina h3 y metodos para el uso de los mismos.
EP2445343B1 (en) 2009-06-25 2021-08-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
KR101721280B1 (ko) 2009-08-17 2017-03-29 인텔리카인, 엘엘씨 헤테로사이클릭 화합물 및 이의 용도
WO2011022489A2 (en) 2009-08-18 2011-02-24 The Johns Hopkins University (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
WO2011033265A1 (en) 2009-09-18 2011-03-24 Almac Discovery Limited Pharmaceutical compounds
EP2480528B1 (en) 2009-09-25 2018-08-29 Oryzon Genomics, S.A. Lysine specific demethylase-1 inhibitors and their use
WO2011042217A1 (en) 2009-10-09 2011-04-14 Oryzon Genomics S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
US8614315B2 (en) 2009-12-25 2013-12-24 Mahmut Bilgic Cefdinir and cefixime formulations and uses thereof
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
WO2011097607A1 (en) 2010-02-08 2011-08-11 Southern Research Institute Anti-viral treatment and assay to screen for anti-viral agent
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
PH12012501841B1 (en) 2010-03-18 2018-01-12 Inst Nat Sante Rech Med Anti-infective compounds
ES2551407T3 (es) 2010-03-18 2015-11-18 Bayer Intellectual Property Gmbh Imidazopirazinas
HRP20170712T1 (hr) 2010-04-02 2017-07-28 Ogeda Sa Novi spojevi selektivnih antagonista nk-3 receptora, farmaceutski pripravak i postupci za uporabu kod poremećaja uzrokovanih nk-3 receptorima
WO2011131697A1 (en) 2010-04-19 2011-10-27 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
EP2560949B1 (en) 2010-04-20 2015-12-02 Università degli Studi di Roma "La Sapienza" Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2
EP2565185A1 (en) 2010-04-28 2013-03-06 Daiichi Sankyo Company, Limited [5,6]heterocyclic compound
WO2011143365A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen heterocyclic compounds useful as pde10 inhibitors
WO2011141713A1 (en) 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
CN102247321A (zh) 2010-05-20 2011-11-23 上海亚盛医药科技有限公司 一种阿朴棉子酚酮自乳化药物传递系统及其制备方法
EP2575808A1 (en) 2010-05-28 2013-04-10 Mahmut Bilgic Combination of antihypertensive agents
CN102295642B (zh) 2010-06-25 2016-04-06 中国人民解放军军事医学科学院毒物药物研究所 2-芳基咪唑并[1,2-a]吡啶-3-乙酰胺衍生物、其制备方法及用途
ES2529119T3 (es) 2010-07-02 2015-02-17 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de canales iónicos
ES2552841T3 (es) 2010-07-12 2015-12-02 Bayer Intellectual Property Gmbh Imidazo[1,2-a]pirimidinas y -piridinas sustituidas
WO2012009475A1 (en) 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
CN101987081B (zh) 2010-07-16 2012-08-08 钟术光 一种控释制剂
CN101987082B (zh) 2010-07-16 2013-04-03 钟术光 固体制剂及其制备方法
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
CN104892525A (zh) 2010-07-29 2015-09-09 奥瑞泽恩基因组学股份有限公司 Lsd1的基于芳基环丙胺的脱甲基酶抑制剂及其医疗用途
CN102397552B (zh) 2010-09-10 2016-06-08 广州自远生物科技有限公司 一种含喹诺酮类的药物复合制剂及其制备方法和应用
WO2012034116A2 (en) 2010-09-10 2012-03-15 The Johns Hopkins University Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
CN103221412B (zh) 2010-09-29 2015-08-19 橘生药品工业株式会社 (氮杂)中氮茚衍生物及其药物用途
US20130303545A1 (en) 2010-09-30 2013-11-14 Tamara Maes Cyclopropylamine derivatives useful as lsd1 inhibitors
JP2013540767A (ja) 2010-10-07 2013-11-07 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ 免疫不全ウイルス転写を調節するための組成物および方法
MX343596B (es) 2010-10-18 2016-11-11 E I Du Pont De Nemours And Company * Sulfonamidas nematocidas.
SG189939A1 (en) 2010-10-21 2013-06-28 Biomarin Pharm Inc Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
WO2012071469A2 (en) 2010-11-23 2012-05-31 Nevada Cancer Institute Histone demethylase inhibitors and uses thereof for treatment o f cancer
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
ES2650744T3 (es) 2010-12-14 2018-01-22 Electrophoretics Limited Inhibidores de la caseína quinasa 1 delta (CK1delta)
UY33805A (es) 2010-12-17 2012-07-31 Boehringer Ingelheim Int ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?.
US9284317B2 (en) 2010-12-17 2016-03-15 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors
US20140135319A1 (en) 2010-12-17 2014-05-15 Bayer Intellectual Property Gmbh 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
JP2013545776A (ja) 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
EP2651946B1 (en) 2010-12-17 2015-05-27 Bayer Intellectual Property GmbH 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
TWI617559B (zh) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
US20140038953A1 (en) 2011-01-21 2014-02-06 The General Hospital Corporation Compositions and methods for cardiovascular disease
WO2012107498A1 (en) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative disorders
EP2712316A1 (en) 2011-02-08 2014-04-02 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
BRPI1101013A2 (pt) 2011-03-03 2013-06-04 Luciano Rabinowicz composiÇço para preparo de bebida energÉtica e bebida energÉtica
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US8853408B2 (en) 2011-03-25 2014-10-07 Glaxosmithkline Intellectual Property (No. 2) Limited Cyclopropylamines as LSD1 inhibitors
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
WO2012156531A2 (en) 2011-05-19 2012-11-22 Oryzon Genomics, S.A. Lysine demethylase inhibitors for inflammatory diseases or conditions
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
US20140296255A1 (en) 2011-05-19 2014-10-02 Oryzong Genomics, S.A. Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
AU2012265842A1 (en) 2011-06-07 2014-01-23 SPAI Group Ltd. Compositions and methods for improving stability and extending shelf life of sensitive food additives and food products thereof
PH12013502612A1 (en) 2011-06-20 2014-04-28 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201311149A (zh) 2011-06-24 2013-03-16 Ishihara Sangyo Kaisha 有害生物防治劑
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
JP6111195B2 (ja) 2011-08-09 2017-04-05 武田薬品工業株式会社 シクロプロパンアミン化合物
DK2744330T3 (da) 2011-08-15 2020-09-07 Univ Utah Res Found Erstattede (e)-n'-(1-phenylethyliden) benzohydrazid-analoger som histone-demethylase-hæmmere
WO2013033688A1 (en) 2011-09-01 2013-03-07 The Brigham And Women's Hospital, Inc. Treatment of cancer
US9273343B2 (en) 2011-09-02 2016-03-01 Promega Corporation Compounds and methods for assaying redox state of metabolically active cells and methods for measuring NAD(P)/NAD(P)H
US9643970B2 (en) 2011-10-10 2017-05-09 H. Lundbeck A/S Substituted imidazo [1,5-a]pyrazines as PDE9 inhibitors
IN2014CN03337A (es) 2011-10-20 2015-07-03 Oryzon Genomics Sa
CL2014000988A1 (es) 2011-10-20 2014-11-03 Oryzon Genomics Sa Compuestos derivados de (aril o heteroaril) ciclopropilamida, inhibidores de lsd1; procedimiento para prepararlos; composicion farmaceutica que los comprende; y metodo para tratar o prevenir cancer, una enfermedad neurologica, una infeccion viral y la reactivacion viral despues de la latencia.
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
ITMI20111971A1 (it) 2011-10-28 2013-04-29 Mesogenics Srl Inibitori dell'enzima lsd-1 per l'induzione del differenziamento osteogenico
US9266881B2 (en) 2011-11-14 2016-02-23 Merck Sharp & Dohme Corp. Triazolopyridinone PDE10 inhibitors
CA2857964A1 (en) 2011-12-05 2013-06-13 Brandeis University Treatment of amyloidosis by compounds that regulate retromer stabilization
WO2014096985A2 (en) 2012-12-19 2014-06-26 Wockhardt Limited A stable aqueous composition comprising human insulin or an analogue or derivative thereof
US20150051202A1 (en) 2012-03-07 2015-02-19 Merck Patent Gmbh Triazolopyrazine derivatives
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
CN102579381B (zh) 2012-03-30 2013-07-10 河南中帅医药科技发展有限公司 盐酸胍法辛缓释制剂及其制备方法
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
WO2014002051A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
CN102772444A (zh) 2012-07-06 2012-11-14 周明千 中药超微破壁口服片剂饮片的加工方法
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
SG11201503299YA (en) 2012-09-28 2015-06-29 Univ Vanderbilt Fused heterocyclic compounds as selective bmp inhibitors
JP6457942B2 (ja) 2012-10-05 2019-01-23 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
CA2887598A1 (en) 2012-10-12 2014-04-17 Takeda Pharmaceutical Company Limited Cyclopropanamine compound and use thereof
US9757379B2 (en) 2012-11-14 2017-09-12 The Board Of Regents Of The University Of Texas System Inhibition of HIF-2α heterodimerization with HIF1β (ARNT)
US9388123B2 (en) 2012-11-28 2016-07-12 Kyoto University LSD1-selective inhibitor having lysine structure
US9144555B2 (en) 2012-11-30 2015-09-29 Darlene E. McCord Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD1 inhibition
EP2740474A1 (en) 2012-12-05 2014-06-11 Instituto Europeo di Oncologia S.r.l. Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
CN103054869A (zh) 2013-01-18 2013-04-24 郑州大学 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用
CN103933036B (zh) 2013-01-23 2017-10-13 中国人民解放军军事医学科学院毒物药物研究所 2‑芳基咪唑并[1,2‑α]吡啶‑3‑乙酰胺衍生物在制备防治PTSD的药物中的用途
EP2956441A4 (en) 2013-02-18 2016-11-02 Scripps Research Inst MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
WO2014164867A1 (en) 2013-03-11 2014-10-09 Imago Biosciences Kdm1a inhibitors for the treatment of disease
EP2971007A4 (en) 2013-03-13 2017-03-22 Australian Nuclear Science And Technology Organisation Transgenic non-human organisms with non-functional tspo genes
US20140343118A1 (en) 2013-03-14 2014-11-20 Duke University Methods of treatment using arylcyclopropylamine compounds
AU2014236348B2 (en) 2013-03-14 2018-05-10 Epizyme, Inc. Combination therapy for treating cancer
US9918983B2 (en) 2013-05-30 2018-03-20 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Suicidal LSD1 inhibitors targeting SOX2-expressing cancer cells
CA2915817C (en) 2013-06-19 2022-12-13 University Of Utah Research Foundation Substituted (e)-n'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors
SMT202000071T1 (it) 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
DK3030323T3 (da) 2013-08-06 2019-07-15 Imago Biosciences Inc Kdm1a-inhibitorer til behandlingen af sygdom
US9186391B2 (en) 2013-08-29 2015-11-17 Musc Foundation For Research Development Cyclic peptide inhibitors of lysine-specific demethylase 1
US9556170B2 (en) 2013-08-30 2017-01-31 University Of Utah Research Foundation Substituted-1H-benzo[d]imidazole series compounds as lysine-specific demethylase 1 (LSD1) inhibitors
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
CN105658209A (zh) 2013-09-13 2016-06-08 拜耳制药股份公司 含有瑞法美替的药物组合物
KR101568724B1 (ko) 2013-11-13 2015-11-12 서울대학교산학협력단 신규한 화합물, 이의 생산 방법, 및 히스톤 디메틸라제 저해제로서 이의 용도
DK3080100T3 (da) 2013-12-11 2023-02-06 Celgene Quanticel Res Inc Hæmmere af lysinspecifik demethylase-1
RS59534B1 (sr) 2014-02-13 2019-12-31 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
PH12020552066A1 (en) 2014-02-13 2022-05-11 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
ES2672797T3 (es) 2014-02-13 2018-06-18 Incyte Corporation Ciclopropilaminas como inhibidores de LSD1
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015145145A1 (en) 2014-03-24 2015-10-01 Cipla Limited Pharmaceutical composition comprising lapatinib
CN103893163B (zh) 2014-03-28 2016-02-03 中国药科大学 2-([1，1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用
CN106458994B (zh) 2014-04-02 2019-09-13 百时美施贵宝公司 联芳激酶抑制剂
EA034197B1 (ru) 2014-04-11 2020-01-16 Такеда Фармасьютикал Компани Лимитед Циклопропанаминовое соединение и его применение
EP2933002A1 (en) 2014-04-11 2015-10-21 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and proton pump inhibitors
EP2929884A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and h2-receptor antagonists
CN103961340B (zh) 2014-04-30 2019-06-25 南通中国科学院海洋研究所海洋科学与技术研究发展中心 一类lsd1抑制剂及其应用
CA2953005C (en) 2014-05-30 2023-03-14 Ieo - Istituto Europeo Di Oncologia S.R.L. Cyclopropylamine compounds as histone demethylase inhibitors
CN104119280B (zh) 2014-06-27 2016-03-16 郑州大学 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
CN104173313B (zh) 2014-08-25 2017-05-17 杭州朱养心药业有限公司 利伐沙班片剂药物组合物
JP6653116B2 (ja) 2014-08-27 2020-02-26 日本ケミファ株式会社 オルメサルタンのプロドラッグ製剤
AU2015330141B2 (en) 2014-10-08 2019-12-05 F. Hoffmann-La Roche Ag Spirodiamine derivatives as aldosterone synthase inhibitors
CN107743481A (zh) 2015-04-03 2018-02-27 百时美施贵宝公司 用于治疗癌症的吲哚胺2,3‑双加氧酶抑制剂
US10501481B2 (en) 2015-04-03 2019-12-10 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3626720A1 (en) 2015-04-03 2020-03-25 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
MX389824B (es) 2015-08-12 2025-03-20 Incyte Holdings Corp Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1).
CN112656772B (zh) 2015-10-15 2022-05-20 浙江东日药业有限公司 利伐沙班药物组合物
SG11201805645QA (en) 2015-12-29 2018-07-30 Mirati Therapeutics Inc Lsd1 inhibitors
WO2017130933A1 (ja) 2016-01-25 2017-08-03 国立大学法人熊本大学 神経変性疾患治療剤
IL262488B (en) 2016-04-22 2022-08-01 Incyte Corp lsdi inhibitor formulations
BR112019014759A2 (pt) 2017-01-18 2020-03-03 Vanderbilt University Compostos heterocíclicos fundidos como inibidores seletivos de bmp
JP7111733B2 (ja) 2017-03-16 2022-08-02 江蘇恒瑞医薬股▲ふん▼有限公司 ヘテロアリール［４，３－ｃ］ピリミジン－５－アミン誘導体、その製造方法、およびその医薬の使用
IL279829B2 (en) 2018-07-05 2025-05-01 Incyte Holdings Corp Fused pyrazine derivatives as A2A/A2B inhibitors
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same

Also Published As

Publication number Publication date
US10723700B2 (en) 2020-07-28
ZA201801417B (en) 2018-12-19
HRP20250161T1 (hr) 2025-04-11
US11498900B2 (en) 2022-11-15
PT3334709T (pt) 2025-03-03
JP7427363B2 (ja) 2024-02-05
CA2995361A1 (en) 2017-02-16
RS66537B1 (sr) 2025-03-31
AU2016306555B2 (en) 2021-01-28
CO2018002354A2 (es) 2018-08-31
EA035534B1 (ru) 2020-06-30
ECSP18018869A (es) 2018-06-30
TW201718490A (zh) 2017-06-01
WO2017027678A1 (en) 2017-02-16
US20210032203A1 (en) 2021-02-04
TWI765860B (zh) 2022-06-01
PL3334709T3 (pl) 2025-04-14
PH12018500317B1 (en) 2023-01-11
MX389824B (es) 2025-03-20
UA126277C2 (uk) 2022-09-14
AU2016306555A1 (en) 2018-03-15
SG10202001219UA (en) 2020-03-30
EP3334709B1 (en) 2024-12-11
CL2018000374A1 (es) 2018-07-06
SI3334709T1 (sl) 2025-03-31
US20190345106A1 (en) 2019-11-14
SMT202500084T1 (it) 2025-03-12
MY189367A (en) 2022-02-08
IL257390B (en) 2022-06-01
MA42606B1 (fr) 2025-02-28
CR20180152A (es) 2018-08-09
KR20180051523A (ko) 2018-05-16
HK1255427A1 (en) 2019-08-16
BR112018002553A8 (pt) 2023-01-24
MX2018001706A (es) 2018-09-06
CN110402244A (zh) 2019-11-01
CN110402244B (zh) 2023-02-03
FI3334709T3 (fi) 2025-03-05
MA42606A (fr) 2018-06-20
EP3334709A1 (en) 2018-06-20
IL257390A (en) 2018-04-30
LT3334709T (lt) 2025-03-10
ES3011209T3 (en) 2025-04-07
BR112018002553A2 (pt) 2018-09-18
US20170044101A1 (en) 2017-02-16
PH12018500317A1 (en) 2018-08-13
HUE070538T2 (hu) 2025-06-28
US10329255B2 (en) 2019-06-25
EA201890469A1 (ru) 2018-11-30
DK3334709T3 (da) 2025-02-03
NZ740186A (en) 2024-07-05
KR102710120B1 (ko) 2024-09-27
JP2018527339A (ja) 2018-09-20

Similar Documents

Publication Publication Date Title
PE20181175A1 (es) Sales de un inhibidor de lsd1
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
MX374605B (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria.
CU20160183A7 (es) Sales del clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
CR20160496A (es) Inhibidores espirocíclicos sustituidos de la autotaxina
CR20160237A (es) Derivados de la carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
TW201613860A (en) Cyclopropylamines as LSD1 inhibitors
MX2017012558A (es) Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para su uso.
MX381640B (es) Metodos y compuestos agonistas de gip.
SV2017005434A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
MX376164B (es) Composiciones y metodos para tratar el insomnio.
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
CY1123267T1 (el) Κρυσταλλικες μορφες 2-(tpit-boytyλamino)-4-((1r,3r,4r)-3-yδpoξy-4-μεθυλοκυκλοεξυλαμινο)-πυριμιδινο-5-καρβοξαμιδιου
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
BR112016016098A2 (pt) Compostos orgânicos
BR112018016346A2 (pt) processo
MX2018000539A (es) Inhibidores de il-8 para utilizarse en el tratamiento de ciertos trastornos urologicos.
MX380372B (es) Metodo para producir acilsulfamoilbenzamidas.
AR099931A1 (es) Combinaciones de agentes terapéuticos contra cáncer
AR105687A1 (es) Sales de un inhibidor de lsd1
TH1801000840A (th) เกลือของตัวยับยั้งlsd1
BR112013032338A2 (pt) método para melhorar o rendimento de produção para proteína l1 do papilomavírus humano